+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein



Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein



Official Gazette of the United States Patent & Trademark Office Patents 1264(3), Nov 19



A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of a VCAM-1/IgG fusion protein.

(PDF emailed within 1 workday: $29.90)

Accession: 035980217

Download citation: RISBibTeXText


Related references

Elevated ICAM-1, VCAM-1 and E-selectin in active inflammatory bowel disease. Gastroenterology 106(4 SUPPL ): A690, 1994

Elevation of soluble VCAM-1 in the serum of patients with inflammatory bowel disease. Gastroenterology 106(4 SUPPL ): A689, 1994

Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. Journal of Immunology 162(1): 486-493, 1999

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.10.Bacterial intestine infections. Nihon Naika Gakkai Zasshi 82(5): 701-707, 1993

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.5.Simple intestinal ulcer. Nihon Naika Gakkai Zasshi 82(5): 679-682, 1993

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.4.Intestinal Behcet's disease. Nihon Naika Gakkai Zasshi 82(5): 675-678, 1993

Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?. World Journal of Gastroenterology 13(15): 2145-2149, 2007

Sa1897 Anti-Tumor Necrosis Factor Treatment of Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Gastroenterology 150(4): S396-S397, 2016

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.6.Ischemic colitis. Nihon Naika Gakkai Zasshi 82(5): 683-687, 1993

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.9.Colitis aphthoid. Nihon Naika Gakkai Zasshi 82(5): 697-700, 1993

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.8.Entamebiasis coli. Nihon Naika Gakkai Zasshi 82(5): 693-696, 1993

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.3.Intestinal tuberculosis. Nihon Naika Gakkai Zasshi 82(5): 669-674, 1993

Inflammatory bowel disease.Advances in diagnosis and treatment.2.Origin and treatment of inflammatory bowel disease.7.Pseudomembranous colitis. Nihon Naika Gakkai Zasshi 82(5): 688-692, 1993

ICAM-1 and VCAM-1 antisense oligonucleotides attenuate leukocyte adhesion and inflammation in a rat model of inflammatory bowel disease. Gastroenterology 118(4 Suppl 2 Part 1): AGA A577, 2000

ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Gut 51(4): 529-535, 2002